News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

BioIndustry Association Welcomes Technology Strategy Board's New Diagnostics for Stratified Medicine Catapult

8/13/2013 9:01:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

13 August 2013 -- Business Secretary Vince Cable has today announced that the Technology Strategy Board will establish a new Diagnostics for Stratified Medicine Catapult in 2015/16, which will help identify and provide the right care for individual patients, allowing businesses to develop new treatments and reducing the cost of healthcare.

Steve Bates, BioIndustry Association (BIA) Chief Executive Officer, said:

"I encourage the sector to engage in the development of this new Catapult, which will complement the work of the Cell Therapy Catapult and the National Biologics Manufacturing Centre.

"It is good to see this ongoing support for the future of the UK life science sector from our government. Many details of the new Catapult still need to be developed but it's already clear that the concept of integrating diagnostics, big data, the management of patient records and therapies is key for the healthcare system of the future.

"I fully expect some of the new £185 million earmarked for Catapults and Catalysts in the last spending review to be used to fund the development of this new initiative and encourage innovative companies to engage in its development. The BIA is excited to play a full role in ensuring the Catapult succeeds in enabling UK life science businesses to deliver jobs and growth."

For further information, please contact Robert Winder, Head of Communications,, 020 7630 2191; mobile 07825 942 934.

Vince Cable outlines a significant expansion in the groundbreaking Catapult centres that help turn great ideas into commercial realities

Technology Strategy Board Catapult Programme update 2012-2013

In the 'Next steps' section of its Catapult Programme update 2012-2013 the Technology Strategy Board said that it will "start the process to scope and establish a Catapult with a focus on 'Diagnostics for Stratification'. The centre will act as a rallying point to enable the linkages between biopharma, diagnostics and healthcare systems. The Catapult will provide the skills and knowledge which businesses can tap into in a growth area where there is significant potential. Diagnostic development (including sensors and engineering), data handling and management and patient cohorts will all play an important role in supporting diagnostic tool development giving more rapid feedback into the healthcare system and for companies developing new treatments"

BioIndustry Association

Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus